Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Background Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate‐to‐severe plaque psoriasis. Real‐world evidence on the effectiveness and safety of tildrakizumab is limited. Objectives To assess the effective...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2023-12, Vol.37 (12), p.2517-2525
Main Authors: Berenguer‐Ruiz, Sonsoles, Aparicio‐Domínguez, Mario, Herranz‐Pinto, Pedro, Ruíz‐Villaverde, Ricardo, López‐Ferrer, Anna, Santos‐Juanes, Jorge, Rodríguez Fernández‐Freire, Lourdes, Hospital‐Gil, Mercedes, Arias‐Santiago, Salvador, Carretero‐Hernández, Gregorio, Mateu‐Puchades, Almudena, Ferran, Marta, Alcázar, Elena, Santos‐Alarcón, Sergio, Garcia‐Latasa de Aranibar, Francisco Javier, Belinchón‐Romero, Isabel, González‐Cantero, Álvaro, Ruíz‐Genao, Diana, Eiris‐Salvado, Noemí, Rocamora‐Durán, Vicenç, Rivera‐Diaz, Raquel, Cueva, Pablo, Daudén, Esteban, Salgado‐Boquete, Laura, Llamas‐Velasco, Mar
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate‐to‐severe plaque psoriasis. Real‐world evidence on the effectiveness and safety of tildrakizumab is limited. Objectives To assess the effectiveness and safety of tildrakizumab at 24 weeks in patients with moderate‐to‐severe plaque psoriasis in routine clinical practice. Methods Retrospective, observational, multicentre study including adult patients with moderate‐to‐severe plaque psoriasis treated with tildrakizumab under real‐life conditions. Patient data were extracted from anonymized electronic medical records. Statistical analysis was performed using SPSS22. Results A total of 190 patients were included. About 53.9% were men with a mean age of 51.45 (SD 3.9) and a mean BMI of 29.13 (SD 6.21). About 79.8% (132 out of 190) of patients had previously received biological therapy (BT) and 17.3% (33 out of 191) had psoriatic arthritis. Baseline PASI was 10.7 (SD 6.53). Up to 109 patients reached Week 24 and at this point mean baseline PASI decreased to 1.7 (SD 4.8), representing an 88.79% mean PASI reduction. At 6 months, 87.1% and 40.3% of the treated patients achieved PASI ≤3 and ≤1, respectively. At Week 24 mean BSA decreased from 13.2 (SD 10.07) to 1.6 (SD 4.40) and mean DLQI went from 12.5 (SD 7.12) to 1.2 (SD 3.27). Multivariate analysis showed no differences when effectiveness was correlated with gender, obesity, psoriatic arthritis or prior exposure to BT. The rate of adverse events (AE) was 5.9% (11 out of 190), where infections were the most frequent AE (4 out of 11). One patient suffered a haemorrhagic ictus and one patient died due to causes unrelated to the study. Conclusion Tildrakizumab was effective and safe in a large cohort of patients with moderate‐to‐severe plaque psoriasis treated in a routine clinical setting.
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.19468